Heart failure & cardiomyopathies
Regional Handling and Prognostic Performance of Circulating Insulin-Like Growth Factor Binding Protein-7 in Heart Failure
Main finding · HF hospitalization or all-cause mortalityResult — go to the resultHazard ratio 1.32 95% CI 1.06–1.64Authors' conclusion
Transorgan regulation of IGFBP-7 is distinct from NT-proBNP. Circulating IGFBP-7 independently predicts adverse outcomes in CHF with a strong prognostic performance when compared with other well-recognized cardiac-specific or noncardiac prognostic markers.
Study context
- Population
- Patients with chronic heart failure (HF) (36% HFpEF); separate non-HF cohort undergoing cardiac catheterization for transorgan gradientsplus non-HF cohort n = 66
- Participants
- 863 patients
- Exposure
- IGFBP-7 ≥110 ng/mL vs IGFBP-7 <110 ng/mL
- Outcome
- Composite of:
- HF hospitalization
- All-cause mortality
Main finding
HF hospitalization or all-cause mortality
Hazard ratio
1.32
95% CI 1.06–1.64
As reported in the abstract
Observational data: associations, not effects.
Further findings
Plasma IGFBP-7 concentration in chronic heart failure (CHF); relation to LV volumes and diastolic function
- IGFBP-7 median (IQR 99-156) ng/mL
- 121
- IGFBP-7 related inversely to LV volumes but directly to diastolic function
Incremental prognostic value of IGFBP-7 beyond clinical predictors plus NT-proBNP, hs troponin-T and hs CRP
- IGFBP-7 had the highest hazard per proportional increment among 5 markers, independent of HF phenotype, and added incremental prognostic value
- P < 0.05
Regional (transorgan) handling of IGFBP-7 vs NT-proBNP (non-HF catheterization cohort, n = 66)
- Renal secretion of IGFBP-7 vs renal extraction of NT-proBNP; possible cardiac extraction of IGFBP-7 vs secretion of NT-proBNP; common hepatic extraction of both
Original publication
Summarised from the published abstract; every number is checked against it